Dr. Kevin Hill -- Pharmaceutical Payment Report
This page provides a comprehensive transparency report for Dr. Kevin Hill, a Dermatology physician based in Lowell, MA. All payment data is sourced from the CMS Open Payments (Sunshine Act) database. Dr. Kevin Hill has received $2,328.03 in total pharmaceutical industry payments across 1 transactions from 1 pharmaceutical companies.
Physician Profile
The following profile information is sourced from the National Provider Identifier (NPI) registry and CMS Open Payments records.
- Full Name: Dr. Kevin Hill
- Medical Specialty: Dermatology
- Practice Location: Lowell, MA, Massachusetts
- NPI Number: 1265636579
- Transparency Score: 75/100
- Payment Records Span: 2025-04-22 to 2025-04-22
Payment Summary
Dr. Kevin Hill has received a total of $2,328.03 in pharmaceutical industry payments across 1 recorded transactions in the CMS Open Payments database. The average payment amount is $2,328.03 per transaction.
- Total Payments Received: $2,328.03
- Number of Transactions: 1
- Average Payment: $2,328.03
- Transparency Score: 75/100 -- This score reflects the overall payment profile relative to peers in Dermatology. A higher score indicates fewer or more routine payments.
- Number of Pharma Relationships: 1 pharmaceutical companies
- Drugs/Devices Referenced: 1 distinct products
Payment Breakdown by Category
The following table shows how Dr. Kevin Hill's pharmaceutical payments break down by payment category. Understanding the mix of payment types provides important context about the nature of the doctor-pharma relationship.
| Payment Category | Amount | Description |
|---|
The largest payment category for Dr. Kevin Hill is Speaking & Education, accounting for 0% ($0.00) of total pharmaceutical payments received. This suggests active involvement in pharmaceutical company advisory and educational programs.
Pharmaceutical Company Relationships
The following pharmaceutical and medical device companies have made payments to Dr. Kevin Hill. Click on any company name to view their full physician payment profile and spending patterns.
| Company | Total Paid | Transactions |
|---|---|---|
| Regeneron Pharmaceuticals | $2,328.03 | 1 |
Dr. Kevin Hill has a financial relationship with Regeneron Pharmaceuticals, receiving $2,328.03 in total. Having a single pharmaceutical company relationship means all payments come from one source, which may indicate a focused consulting or research relationship.
Drugs and Medical Devices Referenced in Payments
The following drugs and medical devices have been referenced in pharmaceutical payments to Dr. Kevin Hill. These references indicate that the payment was related to the marketing, consulting, or clinical use of these products.
- Eylea -- Referenced in payment records from pharmaceutical companies to Dr. Kevin Hill
The presence of a drug or device in a payment record means the pharmaceutical company associated the payment with that product. This is common for consulting fees related to a specific medication, speaking engagements about a product, or research involving a particular drug or device.
AI Transparency Analysis
The following analysis was generated by artificial intelligence based on Dr. Kevin Hill's payment history, specialty peer comparisons, and payment pattern analysis. This analysis is not medical or legal advice.
Kevin Hill has received $2.3K across 1 pharmaceutical payments as a Dermatology physician in Lowell, MA. Top paying companies include Regeneron Pharmaceuticals ($2.3K). The physician received a single payment totaling $2,328 in 2025. This payment originated entirely from Regeneron Pharmaceuticals, indicating a strong relationship with this single company. The payment was associated with the drug Eylea, suggesting a focus on treatments within this therapeutic area.
Patient Guidance: Questions to Ask Your Doctor
If Dr. Kevin Hill is your physician, here is practical guidance on how to understand and discuss pharmaceutical industry relationships:
Patients may want to inquire about any potential conflicts of interest or the specific nature of the relationship between their physician and pharmaceutical companies, especially when a significant portion of payments comes from a single source or is tied to a specific medication. Always feel free to ask your doctor directly about their pharmaceutical relationships.
Peer Comparison: How Dr. Kevin Hill Compares to Other Dermatology Physicians
For a Dermatologist, this payment profile is somewhat unusual given the concentration from a single company and the specific drug listed, which is more commonly associated with ophthalmology.
Recent Payment Records
The following table shows the most recent pharmaceutical industry payments recorded for Dr. Kevin Hill in the CMS Open Payments database. Click on any payment to view the full report.
| Company | Amount | Type | Drug/Device | Date | Conflict Level |
|---|---|---|---|---|---|
| Regeneron Pharmaceuticals | $2,328.03 | general | Eylea | 2025-04-22 | Not Assessed |
Frequently Asked Questions About Dr. Kevin Hill's Pharma Payments
Below are common questions patients ask about physician pharmaceutical payment data.
How much pharma money has Kevin Hill received?
Kevin Hill has received a total of $2.3K across 1 payments from pharmaceutical companies. This data is publicly reported under the CMS Open Payments (Sunshine Act) program.
Is Kevin Hill taking too much pharma money?
Kevin Hill has received $2.3K in pharmaceutical payments. Whether this is "too much" depends on the physician's specialty (Dermatology), the types of payments, and how they compare to peers. The largest payment category is general ($2.3K). Payment does not imply wrongdoing, but patients should be aware and can ask their doctor directly.
What pharma companies pay Kevin Hill?
The top pharmaceutical companies paying Kevin Hill are: Regeneron Pharmaceuticals ($2.3K). These payments cover various categories including consulting, meals, speaking fees, and research grants.
What kinds of payments does Kevin Hill receive?
Kevin Hill's payments by type: general: $2.3K.
Should I switch doctors because of pharma payments?
Pharma payments alone are not typically reason to switch doctors. Many payments are routine (like meals at educational events) and do not indicate compromised care. Focus on: (1) whether your doctor explains treatment options clearly, (2) whether generic alternatives are discussed, (3) the overall pattern of payments, not individual transactions. If you have concerns, ask your doctor directly.
How do Kevin Hill's payments compare to other Dermatology doctors?
To compare, look at the total amount ($2.3K), number of payments (1), and the types of payments received. Dermatology physicians may receive different payment amounts depending on subspecialty, geographic location, and academic affiliation. Use CMS Open Payments data to compare across the specialty.
How can I verify Kevin Hill's payment data?
You can verify this data directly through the CMS Open Payments database at openpaymentsdata.cms.gov. Search by physician name or NPI number (1265636579). All data is reported by pharmaceutical companies and verified by CMS. DoctorPharmaData aggregates this public data for easier access.
Do pharma payments affect prescribing quality?
Research published in JAMA Internal Medicine and other peer-reviewed journals shows a statistical association between pharmaceutical payments and prescribing patterns. However, correlation does not equal causation. Many physician-industry interactions are legitimate (research, education, advisory boards). The Sunshine Act was created to promote transparency so patients can make informed decisions.
What stands out about Kevin Hill's pharma payment profile?
The physician's payment profile is highly concentrated with one company (100%) and one drug (Eylea). Kevin Hill has received $2.3K in total pharma payments.
How does Kevin Hill compare to peers in Dermatology?
For a Dermatologist, this payment profile is somewhat unusual given the concentration from a single company and the specific drug listed, which is more commonly associated with ophthalmology.
Are Kevin Hill's pharma relationships typical for Dermatology?
The single payment received is substantial, suggesting it may be for research, consulting, or a significant educational event.
What should patients of Kevin Hill know about these payments?
Patients may want to inquire about any potential conflicts of interest or the specific nature of the relationship between their physician and pharmaceutical companies, especially when a significant portion of payments comes from a single source or is tied to a specific medication.
What patterns are visible in Kevin Hill's payment history?
The data for 2025 is likely preliminary or represents a future projection, as it's unusual to have complete data for a future year.
Understanding This Doctor Payment Report
This transparency report for Dr. Kevin Hill is based on data from the CMS Open Payments database, which is maintained by the Centers for Medicare and Medicaid Services under the Physician Payments Sunshine Act. Here are important things to understand:
- Payment does not imply wrongdoing. Many pharmaceutical payments represent legitimate professional activities such as consulting on drug development, speaking at medical education events, and conducting clinical research.
- Context matters. A large payment for conducting a clinical trial has very different implications than a large payment for promotional speaking. The payment breakdown by category above provides this context.
- Peer comparison is important. Whether a payment amount is unusual depends heavily on the physician's specialty, geographic location, and career stage. Dermatology physicians may have very different payment norms than physicians in other fields.
- Data may be incomplete. The CMS Open Payments database captures payments from pharmaceutical and medical device manufacturers. It does not include payments from other sources, such as hospitals, insurance companies, or government agencies.
- Reporting thresholds apply. Small payments below certain thresholds may not be individually reported. The totals reflect payments above reporting minimums set by CMS regulations.
About the Physician Payments Sunshine Act
The Physician Payments Sunshine Act, enacted as Section 6002 of the Affordable Care Act in 2010, requires pharmaceutical and medical device companies to report payments and other transfers of value to physicians and teaching hospitals to CMS. This law was designed to increase transparency in the financial relationships between the healthcare industry and medical providers.
Under this law, Dr. Kevin Hill's pharmaceutical payments are publicly disclosed. The types of reportable transactions include consulting fees, compensated speaking or educational activities, honoraria, gifts, entertainment, food and beverages, travel and lodging, education or conference attendance, research grants, charitable contributions, royalties or licenses, current or prospective ownership interests, and direct compensation for services other than consulting.
The Open Payments data for Dr. Kevin Hill and all other physicians can be accessed at the official CMS Open Payments website.
Related Resources
- Dermatology Specialty Payment Data -- See payment patterns for all dermatology physicians
- Massachusetts Physician Payments -- Browse pharmaceutical payments to physicians in Massachusetts
- Dermatology Physicians in Massachusetts -- Compare Dr. Kevin Hill to peers in the same state and specialty
- Regeneron Pharmaceuticals Payment Profile -- View all payments made by Dr. Kevin Hill's largest pharmaceutical partner
- Search for Another Doctor or Company -- Look up any physician or pharmaceutical company in our database
- Official CMS Open Payments Database -- Verify payment data directly with the federal government
- NPI Registry -- Look up Dr. Kevin Hill's NPI (1265636579) in the official provider registry
Data from CMS Open Payments (Sunshine Act). Payment does not imply wrongdoing. AI analysis is not medical or legal advice. Consult your healthcare provider about any concerns.